Theratechnologies (TSE:TH) had its price objective lowered by Mackie from C$8.15 to C$7.00 in a research report released on Friday, BayStreet.CA reports. The brokerage currently has a hold rating on the stock.
Other analysts also recently issued research reports about the company. National Bank Financial raised their price objective on Wesdome Gold Mines from C$6.00 to C$6.25 and gave the stock an outperform rating in a research report on Friday. Royal Bank of Canada set a $184.00 target price on Jazz Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, July 3rd. Finally, Stifel Nicolaus started coverage on Theratechnologies in a report on Tuesday, May 14th. They set a buy rating and a C$15.00 price target for the company. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Theratechnologies currently has an average rating of Buy and an average target price of C$9.56.
Shares of TSE:TH opened at C$5.85 on Friday. The firm’s 50 day simple moving average is C$6.75. Theratechnologies has a twelve month low of C$5.17 and a twelve month high of C$11.45. The company has a market cap of $449.88 million and a P/E ratio of -92.86. The company has a debt-to-equity ratio of 159.35, a quick ratio of 2.09 and a current ratio of 2.69.
Institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in shares of Theratechnologies in the first quarter valued at about $96,000. Mesirow Financial Investment Management Inc. acquired a new position in Theratechnologies during the first quarter worth approximately $328,000. LLBH Private Wealth Management LLC bought a new stake in shares of Theratechnologies during the first quarter worth approximately $1,735,000. Finally, Monarch Partners Asset Management LLC bought a new stake in shares of Theratechnologies during the first quarter worth approximately $4,256,000.
Theratechnologies Company Profile
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.
Further Reading: What are Bollinger Bands?
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.